Wondering if NAD+ is right for you? Take the 3-min clinical quiz.
See if you qualify →The “Wolverine peptide” is a nickname for a stack of BPC-157 and TB-500, two regenerative peptides used by some clinics for tissue repair, inflammation, and recovery. Neither peptide is FDA-approved for any medical use, human trials are limited, and safe access depends on a licensed clinician and a state-licensed compounding pharmacy.
What is the Wolverine peptide?
Wolverine peptide usually means a two-peptide stack: BPC-157, also called Body Protection Compound-157, and TB-500, a synthetic peptide modeled after parts of thymosin beta-4. The nickname comes from the comic-book character known for rapid healing, but the name is marketing language, not a medical term.
Where the nickname comes from
Clinics and wellness sites use “Wolverine” to describe a repair-focused peptide stack. The claim is that BPC-157 may support local tissue signaling while TB-500 may support cell movement and new blood-vessel signaling. The honest 2026 view is that this is biologically plausible, but not proven in large human trials.
BPC-157 vs TB-500 at a glance
| Peptide | Full name or parent protein | Main research focus | Human evidence | FDA status |
|---|---|---|---|---|
| BPC-157 | Body Protection Compound-157 | Tendon, ligament, muscle, gut, nerve, and blood-vessel signaling in animal studies | Very limited published human evidence for injury recovery | Not FDA-approved for any medical use |
| TB-500 | Synthetic peptide related to thymosin beta-4 | Cell migration, angiogenesis, inflammation signaling, and wound models | Human studies mainly involve thymosin beta-4 or related ophthalmic formulations, not the common wellness-clinic TB-500 stack | Not FDA-approved for any medical use |
How does the Wolverine stack work in the body?
BPC-157 and TB-500 are described as regenerative peptides because they appear to affect repair signals in preclinical models. That does not mean they rebuild tissue on command; it means researchers have seen effects on inflammation, blood-vessel growth, collagen-related pathways, and cell movement in controlled models.
BPC-157: local tissue repair signals
BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein sequence first studied in gastric juice. In animal models, researchers have reported effects on tendon healing, blood-vessel formation, nitric-oxide signaling, and inflammation pathways, but these findings have not been confirmed in large human trials for injury recovery 4 5.
In a rat Achilles tendon study, BPC-157 was associated with improved tendon outgrowth and cell spreading compared with controls. This is interesting for tendon biology, but animal results do not predict a person’s pain relief, return to sport, or recovery time 5.
TB-500: cell migration and angiogenesis
TB-500 is commonly described as a fragment or analog related to thymosin beta-4, a naturally occurring protein involved in actin binding, cell movement, inflammation signaling, and tissue repair. Thymosin beta-4 has been studied in wound and eye-surface healing, including human ophthalmology trials, but that evidence should not be treated as proof for wellness-clinic TB-500 injections 7 8.
Why people stack them
The theory behind the 2-peptide stack is simple: BPC-157 may act more locally on injured tissue signals, while TB-500 may have broader effects on cell migration and angiogenesis. The trade-off is that combination-specific human trials are lacking, so side effects, best candidates, and long-term risks are not well defined.
What does the research actually show?
Wolverine peptide research is much stronger in animals than in humans. The main signal is “promising but early,” especially for BPC-157; any benefit claim should be paired with the limits of the evidence and the unknowns around safety.
Animal evidence
BPC-157 has been studied in rats for tendon, ligament, muscle, nerve, gut, and vascular injury models. Reviews and animal studies describe possible effects on fibroblast migration, collagen organization, nitric-oxide pathways, and angiogenesis, but these are not FDA-reviewed outcomes and are not proof of human benefit 4 5 6.
Thymosin beta-4 research also supports a biologic role in repair. In peer-reviewed studies, thymosin beta-4 has been linked with keratinocyte migration, corneal repair, and wound-healing pathways, while common side effects in human eye studies included local irritation or eye symptoms depending on the formulation 7 8.
Human evidence
For BPC-157, published human efficacy data for tendon, ligament, muscle, post-surgical recovery, or chronic pain are very limited. FDA has also raised safety concerns for BPC-157 as a bulk drug substance considered for compounding, including a lack of adequate safety data for systemic use 1.
For thymosin beta-4–related products, human research exists in areas like dry eye and corneal healing. In a phase 2 study of a thymosin beta-4 ophthalmic preparation, researchers evaluated eye-surface healing rather than whole-body injury recovery, so it cannot be used to prove TB-500 benefits for sports injuries or chronic pain 8.
What is still unknown
- Whether BPC-157 or TB-500 improves pain, function, or recovery time in large, well-controlled human trials.
- Which patients, if any, are most likely to benefit.
- How long systemic effects last after a course of injections.
- Whether repeated cycles change cancer risk, immune function, scarring, or abnormal blood-vessel growth.
- How the stack interacts with surgery, anticoagulants, diabetes medications, GLP-1 medications, hormones, or immune-active therapies.
What conditions do people use it for?
BPC-157 plus TB-500 is most often marketed for tendon injuries, ligament injuries, muscle strains, post-surgical recovery, and chronic pain. These uses are not FDA-approved, and the evidence is not strong enough to promise faster recovery or less pain.
Tendon, ligament, and muscle injuries
Animal studies of BPC-157 include Achilles tendon and tendon-to-bone healing models. Researchers have reported improved healing markers in animals, but people with tendon pain still need a real diagnosis, activity planning, physical therapy when appropriate, and monitoring for red flags like rupture or infection 5 6.
Post-surgical recovery
Some people ask about the Wolverine stack after orthopedic or cosmetic surgery. This is a high-risk time to self-experiment because peptides may affect inflammation, blood-vessel signaling, scarring, infection risk, and medication interactions; surgery recovery should be coordinated with the operating clinician.
Chronic pain
Chronic pain is not one disease. It can come from tendon injury, joint disease, nerve irritation, autoimmune disease, central pain sensitization, or other causes. Because Wolverine peptide claims are not backed by large pain trials, the safer first step is a clinician-led evaluation rather than buying a “research use only” vial online.
Is the Wolverine peptide safe? Side effects and risks
Wolverine peptide side effects are not fully known because large human safety trials are missing. The risk picture includes the peptide itself, the route of use, the person’s medical history, and whether the product comes from a licensed pharmacy or an unlicensed research-chemical seller.
Reported and possible side effects
- Injection-site pain, redness, bruising, swelling, or infection risk.
- Headache, nausea, flushing, dizziness, or fatigue reported anecdotally in clinical settings, though strong incidence data are lacking.
- Possible immune reactions or allergy-like reactions with any injected peptide.
- Unknown effects in pregnancy, breastfeeding, active cancer, immune disease, severe liver disease, severe kidney disease, or after recent surgery.
- Theoretical concern around abnormal angiogenesis because repair pathways can involve blood-vessel growth.
Contamination and research-use-only products
The biggest practical safety gap is often the supply chain. FDA has repeatedly warned that poor compounding or unapproved drug manufacturing can expose patients to sterility, potency, and contamination problems, especially with injectable products 10.
A state-licensed 503A compounding pharmacy is different from a website selling “research use only” vials without a prescription. A legitimate medical path includes a clinician evaluation, a prescription when appropriate, pharmacy quality controls, and follow-up for side effects.
Who should avoid it or be extra cautious
People who are pregnant, breastfeeding, trying to conceive, undergoing cancer treatment, immunocompromised, scheduled for surgery, taking anticoagulants, or competing in tested sports should not self-start BPC-157 or TB-500. These groups have higher uncertainty, higher stakes, or clear sports-rule concerns.
Is BPC-157 or TB-500 FDA-approved or legal?
BPC-157 and TB-500 are not FDA-approved for any medical use. Legal access, when available, depends on federal and state compounding rules, a valid clinician-patient relationship, and a prescription from a licensed provider.
FDA status in 2026
FDA’s compounding framework does not make a peptide “approved” just because a pharmacy can compound it under certain conditions. FDA has placed BPC-157 among bulk substances with safety concerns in the 503A evaluation process, which is one reason clinician oversight and pharmacy legitimacy matter 1.
WADA and sports bans
BPC-157 appears on the World Anti-Doping Agency prohibited list under non-approved substances. That means athletes subject to drug testing should not use it, even if a wellness clinic markets it as a recovery peptide 3.
Why a licensed provider matters
A licensed provider can review your diagnosis, medications, pregnancy status, cancer history, surgery plans, allergies, and sport-testing rules. That clinical screen is the key difference between supervised care and guessing with an online vial.
How is the Wolverine peptide dosed and taken?
There is no FDA-approved dose or duration for BPC-157, TB-500, or the Wolverine stack. Because there is no approved label, any dosing plan should be treated as individualized medical decision-making, not internet instructions.
Injection vs oral
BPC-157 is sold online in injectable and oral forms, while TB-500 is most often marketed as an injection. Injection adds sterility and technique risks; oral use adds uncertainty about absorption and whether the same tissue effects seen in animal injection studies would apply.
Typical cycle lengths
You may see clinics advertise short courses, often framed in weeks rather than years. Those timeframes are not based on an FDA-approved label, and they should not replace a provider’s review of the injury, imaging, surgery plan, medications, and goals.
Why dosing must be provider-guided
Small peptides can have broad biologic effects, and more is not automatically better. A clinician should decide whether a peptide is appropriate at all, whether another diagnosis is being missed, and whether side effects or lack of progress mean the plan should stop.
How much does the Wolverine peptide cost?
Wolverine peptide cost varies widely because BPC-157 and TB-500 are not approved drugs with standard retail pricing. Price depends on the clinician visit, pharmacy, formulation, amount dispensed, shipping, follow-up, and whether testing or imaging is part of care.
Be careful with very low prices from no-prescription vendors. With injectable peptides, the cheapest option may carry the highest risk if identity, sterility, potency, storage, and handling are not controlled.
| Access route | What it may include | Main concern |
|---|---|---|
| Licensed clinician + 503A pharmacy | Medical review, prescription if appropriate, pharmacy compounding, follow-up | Still not FDA-approved; benefit and long-term safety remain uncertain |
| Wellness clinic without clear pharmacy details | May include a visit and peptide package | Hard to verify sourcing, sterility, and whether the plan fits your health history |
| Research-use-only website | No prescription, vial shipped directly | No real clinical screening; higher concern for contamination, wrong ingredient, or unsafe use |
How can you access peptides safely through a licensed provider?
Chia does not offer BPC-157 or TB-500. We are covering the Wolverine stack for education because many patients ask about it, and because the safest general model for any prescription peptide is a licensed provider plus a state-licensed 503A compounding pharmacy.
At Chia, our available longevity treatments follow that clinician-reviewed model. For related goals, we offer sermorelin in injection, nasal spray, and tablet forms; GHK-Cu cream for skin-focused care; and multi-treatment protocols such as Foundation Longevity and Glow. These are not substitutes for BPC-157 or TB-500, and they have different mechanisms, risks, and candidacy rules.
| Option | Chia availability | Forms listed in Chia catalog | How to think about it |
|---|---|---|---|
| BPC-157 | Not offered by Chia | None | Education only; not FDA-approved for any medical use |
| TB-500 | Not offered by Chia | None | Education only; not FDA-approved for any medical use |
| Sermorelin | Offered by Chia | Injection, nasal spray, tablets | A growth-hormone secretagogue option reviewed by a licensed provider |
| GHK-Cu | Offered by Chia | Cream | A skin-focused copper peptide option |
| Foundation Longevity | Offered by Chia | Sermorelin injection + NAD+ injection + glutathione injection | A multi-treatment longevity protocol reviewed through Chia’s online care model |
Chia care starts with a short online health questionnaire. A licensed US provider reviews it and prescribes only when clinically appropriate; prescriptions are never guaranteed. If prescribed, medications are compounded in the US by state-licensed 503A pharmacies and shipped to your door.
BPC-157 vs TB-500: which one has stronger evidence?
BPC-157 vs TB-500 is not a simple winner-takes-all choice. BPC-157 has many animal studies in injury models, while thymosin beta-4–related research has more human ophthalmology work; neither proves the common Wolverine stack improves whole-body recovery.
If your main question is tendon, ligament, or muscle recovery, BPC-157 is the peptide most often discussed because of animal repair models. If your main question is cell migration and wound biology, thymosin beta-4 research is relevant, but TB-500 sold in wellness settings is not the same as an FDA-approved wound-healing drug 5 7 8.
What peptides stack well with the Wolverine peptide?
Peptide stacking is common in clinical and research practice, but combination-specific human trials are usually missing. Stacks should be viewed as clinician-supervised experiments with clear stop rules, not as DIY protocols.
BPC-157 + TB-500
This is the classic Wolverine stack: BPC-157 is used for local repair signaling, while TB-500 is used for broader cell migration and angiogenesis concepts. The safety caveat is that the combination has not been proven in large human trials, and both injection risk and long-term biologic uncertainty remain.
GHK-Cu + repair-focused peptides
GHK-Cu is a copper peptide studied for skin biology, collagen-related signaling, and wound models; Chia offers GHK-Cu cream, not injectable BPC-157 or TB-500. The safety caveat is that skin-focused topical care should not be expected to act like systemic injury-recovery treatment.
Sermorelin + recovery goals
Sermorelin is a growth-hormone–releasing hormone analog used in longevity medicine to support the GH-axis under clinician supervision; Chia offers sermorelin as injections, nasal spray, and tablets. The safety caveat is that GH-axis therapies have their own screening needs and should not be stacked with other peptides without medical oversight.
Frequently asked questions
There is no FDA-approved duration for BPC-157, TB-500, or the Wolverine stack. Clinics may advertise short courses, but the right answer depends on the diagnosis, goals, side effects, surgery plans, medications, and clinician judgment.
There is not enough high-quality human safety data to say BPC-157 is liver-safe or liver-toxic. People with liver disease, heavy alcohol use, abnormal labs, cancer history, or multiple medications should not self-start it.
Public figures have discussed peptides online, but that should not guide medical care. A podcast mention is not a diagnosis, a prescription, or safety evidence for your body.
There is no standard price because BPC-157 and TB-500 are not FDA-approved drugs with normal retail pricing. Cost depends on the clinician, pharmacy, formulation, amount dispensed, shipping, and follow-up.
Do not stack BPC-157 or TB-500 with GLP-1 medications, sermorelin, hormones, anticoagulants, or post-surgery medications without clinician oversight. Combination-specific human safety data are limited.
No. BPC-157 is not FDA-approved for any medical use, and compounded medications are not FDA-approved. Benefit claims for compounded BPC-157 are not FDA-evaluated outcomes data.
Yes. BPC-157 is on the World Anti-Doping Agency prohibited list under non-approved substances. Competitive athletes subject to testing should avoid it.
Yes. AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health. A licensed provider still reviews the request, and a prescription is never guaranteed.
References
- 1.U.S. Food and Drug Administration. Category 2 Bulk Drug Substances Under Evaluation Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, updated 2024.
- 2.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting Materials and Announcements, 2026.
- 3.World Anti-Doping Agency. The 2026 Prohibited List: International Standard, 2026.
- 4.Sikirić P, Seiwerth S, Rucman R, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Current Pharmaceutical Design, 2020.
- 5.Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic Potential of Pro-angiogenic BPC157 Is Associated with VEGFR2 Activation and Up-regulation. Journal of Molecular Medicine, 2017.
- 6.Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The Promoting Effect of Pentadecapeptide BPC 157 on Tendon Healing Involves Tendon Outgrowth, Cell Survival, and Cell Migration. Journal of Applied Physiology, 2011.
- 7.Goldstein AL, Hannappel E, Kleinman HK. Thymosin Beta4: Actin-Sequestering Protein Moonlights to Repair Injured Tissues. Trends in Molecular Medicine, 2005.
- 8.Sosne G, Qiu P, Kurpakus-Wheater M, Matthew H. Thymosin Beta 4 and Corneal Wound Healing: Visions of the Future. Annals of the New York Academy of Sciences, 2010.
- 9.Dunn SP, Heidemann DG, Chow CY, et al. Treatment of Chronic Nonhealing Neurotrophic Corneal Epithelial Defects With Thymosin Beta 4. Annals of the New York Academy of Sciences, 2010.
- 10.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers, 2024.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if NAD+ is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
